High Blood Sugar and Low Weight Increase Ketoacidosis Risk in SGLT2 Inhibitor Users
Patients with high glucose, low body weight or prior ketoacidosis on SGLT2 inhibitors face higher serious adverse event risk, especially during infection or acute illness.